Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth
Fennec Pharmaceuticals (FENC) reported record-breaking financial results for the third quarter of 2026, characterized by a 56% year-over-year increase in net product sales to $19.4 million. The company demonstrated strong operating leverage, with Non-GAAP Adjusted EBITDA rising to $5.8 million from $2 million in the prior-year period, resulting in an improved margin of 30%. This growth was driven by a surge in patient enrollments and quarterly infusions, which rose 58% compared to the previous quarter. The company's strategic 'Project Ignite' expansion has successfully increased its target physician accounts from 1,300 to 5,000. Fennec maintains a robust balance sheet with $48.7 million in cash and zero debt. While management noted potential long-term timelines for commercializing PEDMARK in the Japanese market, the current focus remains on expanding clinical evidence for broader adult and metastatic patient populations.